AstraZeneca
is one of the world's leading pharmaceutical
companies. Backed by a strong research
base and extensive manufacturing
and commercial skills, the company
provides a powerful range of products
for six important areas of healthcare
- gastrointestinal, cardiovascular,
cancer, respiratory, neurosciences
and infection. With its headquarters
based in UK, AstraZeneca has its
R&D facilities basedin Sweden,
USA, Japan & India. The company
sells its products in over 100 countries,
manufactures in 27 and has major
research centres in 11. It employs
over 65,000 people worldwide and
values the diversity of skills and
abilities that they bring to the
business. R&D is based in Sweden,
the UK, the USA, Canada, France,
India & Japan. The company is
recognised as having one of the
best development pipelines in the
industry and spends over $14 million
each working day to maintain a flow
of new medicines designed to meet
patients’ needs. AstraZeneca invests
over US$ 3.4 billion a year on R&D
activities including Discovery Research.
The company worldwide sales in 2005
totalled $24 billion.
AstraZeneca
in India has its R & D, Manufacturing and Marketing offices in Bangalore, thus bringing to India an entire package of experience and investment.
AstraZeneca
India Pvt. Limited (AZIPL)
is an integral part of the global organisation with a mandate to discover new chemical entities for the treatment of infectious diseases of the developing world. The Company, with its state-of-the-art facility in Bangalore, is dedicated to the
“ Discovery of Novel Therapies for the Developing World diseases”, an unique and brave commitment from one of the world’s leading pharmaceutical companies in the world, a recognition of the talent in India and the environment at Bangalore, a pledge to work together to combat diseases of the developing world like Tuberculosis, which needs a major research thrust to find newer therapies. The R&D facility in India has >90 scientists of international repute working together as a team, contributing effectively to the goal of discovering new and novel therapeutic agents.
The new state-of-the-art Process R&D facility, adjacent to the recently built R&D facility, covering 6000 sq mts on a 3.5 acre plot, will be built to house a team up to 50 more scientists plus associated support staff. The co-location of the Discovery and Process R&D scientists will help AstraZeneca to maximize the scientific interactions and enable shared use of the R&D infrastructure.
AstraZeneca Research Foundation
India (AZREFI) organizes
seminars, symposia and workshops
on subjects at the cutting edge
of biomedical and pharmaceutical
sciences thereby supporting education
and technological innovation in
these areas.
AstraZeneca
Pharma India Limited (AZPIL),
the Marketing Company, has interests
in six crucial areas of healthcare:
Cardiovascular
(with products like Betaloc,
Seloken XL, Imdur, Ramace &
Plendil); Respiratory
( with products like Rhinocort,
Mits Linctus, Bricarex & Bricanyl)
; Maternal Healthcare
(Prostodin, Cerviprime, Primiprost
& Partocin); Oncology
(Zoladex & Arimidex, Nolvadex,
Iressa & Casodex) ;
Infection (Meronem
& Vancocin CP), Pain
Control & Anaesthesia
(Xylocaine & Sensorcaine).
The Company maintains a high ethical
standard of business practice. Products
are promoted in a customer focused
and value-adding manner, through
scientific dissemination of information
to the medical fraternity.
Manufacturing
AZPIL’s manufacturing facility spread
across 69 acres of lush, green environs
at Yelahanka, Bangalore, has been
rated as one of the finest in South
East Asia. It has a sophisticated
production facility designed to
meet the most stringent international
standards, conforming to WHO cGMP
(current Good Manufacturing Practices)
norms. We are an ISO 14001 certified
company and we have a full-fledged
environment management system in
place. We have also, in June 2005,
been presented the Golden Peacock
Environment Management Award from
World Environment Foundation for
the year 2004-2005.